Combination of Talimogene Laherparepvec (modified Herpes Virus) with atezolizumab (monoclonal antibody) in patients with residual breast cancer after conventional chemotherapy during the early stage of the disease.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508550-25-00

Enrollment

Registered

2024-04-26

Start date

2018-12-10

Completion date

2025-03-18

Last updated

2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre and post-menopausal women with resectable primary breast cancer and presence of residual disease after neoadjuvant chemotherapy

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026